Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (355)	1/28/1999 6:02:00 PM
From: Biomaven	Read Replies (1) of 712

I believe CNTO was down because IMNX came out with excellent results for RA in a NEJM article. Sales for Integrilin are still miniscule compared with Reopro, which sold $108 million last quarter: From a CBS MarketWatch release on CORR: The South San Francisco, Calif.-based company said it sold, along with partner Schering-Plough (SGP), $8.4 million worth of its Integrilin product during the quarter. Since Integrilin's approval, the company said it sold $12.2 million worth of the product. Integrilin is a shot that helps prevent heart attacks. It was approved by the Food and Drug Administration in May. Full release at: cbs.marketwatch.com Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next